Liver cancer: time to evolve trial design after everolimus failure.

Liver cancer: time to evolve trial design after everolimus failure.

Item
http://www.wikidata.org/entity/Q54332985
Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinomaAngiogenesis Inhibitors for the Treatment of Hepatocellular CarcinomaPrognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma.Personalized management of hepatocellular carcinoma based on molecular information: future prospects.Long non-coding RNA AOC4P suppresses hepatocellular carcinoma metastasis by enhancing vimentin degradation and inhibiting epithelial-mesenchymal transitionLong noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition.MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.Novel drugs in clinical development for hepatocellular carcinoma.Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription.Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cellsMelatonin suppresses hepatocellular carcinoma progression via lncRNA-CPS1-IT-mediated HIF-1α inactivation.HIF-2α activated lncRNA NEAT1 promotes hepatocellular carcinoma cell invasion and metastasis by affecting the epithelial-mesenchymal transition.Corylin Suppresses Hepatocellular Carcinoma Progression via the Inhibition of Epithelial-Mesenchymal Transition, Mediated by Long Noncoding RNA GAS5.Multimodality Molecular Imaging-Guided Tumor Border Delineation and Photothermal Therapy Analysis Based on Graphene Oxide-Conjugated Gold Nanoparticles Chelated with Gd.
P2860

Liver cancer: time to evolve trial design after everolimus failure.

Item
http://www.wikidata.org/entity/Q54332985
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Liver cancer: time to evolve trial design after everolimus failure.
@en
Liver cancer: time to evolve trial design after everolimus failure.
@nl
type
label
Liver cancer: time to evolve trial design after everolimus failure.
@en
Liver cancer: time to evolve trial design after everolimus failure.
@nl
prefLabel
Liver cancer: time to evolve trial design after everolimus failure.
@en
Liver cancer: time to evolve trial design after everolimus failure.
@nl
P1433
P1476
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Liver cancer: time to evolve trial design after everolimus failure.
@en
P2860
P304
P31
P356
10.1038/NRCLINONC.2014.136
P407
P433
P478
P50
P577
P698